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Abstract 
Nuclear factor-κB (NF-κB) is one of the main regulators of inflammatory 
and immune responses. It is a family of transcription factors composed of five 
members: RelA, RelB, cRel, NF-κB1 (p105/p50), and NF-κB2 (p100/p52). Homo- 
and hetero-dimers of family members are inhibited by inhibitor of κB (IκB) family 
members and activated by IκB kinase (IKK) family members. The IKK family is 
comprised of IKKγ, IKKα, and IKKβ. The focus of my dissertation delves into the 
role of NF-κB activation by IKKβ in both an immunotherapy setting and its role in 
T cell mediated anti-tumor immune responses. 
 A central focus of immunotherapy is to develop vaccine adjuvants that are 
capable of enhancing a protective adaptive immune response. Microbial 
adjuvants in vaccines activate key transcription factors, including NF-κB and 
interferon response factors (IRF). The individual role of these transcription factors 
in successful vaccines is not clear. We used constitutively active IKKβ (CA-IKKβ) 
expressed in an adenoviral vector (AdIKK) to determine the role of classical NF-
κB activation in a vaccine-induced immune response. In an in vivo model, AdIKK 
induced rapid and sustained NF-κB-driven inflammation in the lungs compared to 
the control virus. AdIKK infection had no impact on the magnitude of T cell 
activation as measured by IFN-γ production; however pulmonary inflammation 
 vi 
 
resulted in increased cellularity of draining lymph nodes (LN) at early timepoints 
resulting in increased early antibody and T cell responses. Taken together, these 
findings show that IKKβ-induced NF-κB activation of an inflammatory response 
affects the kinetics, but not the magnitude of the adaptive immune response. 
 NF-κB is activated in many tumor types and contributes to the progression 
of cancer by suppressing apoptosis, and enhancing proliferation, angiogenesis 
and metastasis. NF-κB is also activated in other cells within the tumor 
microenvironment and promotes inflammation initiated by neutrophils and 
macrophages. In addition to inflammatory cells, T cells can be found within the 
tumor microenvironment and are associated with improved patient survival. 
Using CA-IKKβ, we sought to determine if NF-κB activation in tumor cells could 
promote T cell mediated tumor immunity. In both primary tumors and a 
metastatic tumor model, we found that NF-κB expression in tumors rendered 
immunogenic through expression of Kb-OVA led to tumor rejection or growth 
suppression. Tumor regression was mediated by increased CD8 T cell 
recruitment by chemokines. Microarray results showed increases in T cell 
chemokines, including CCL2 and CCL5. Knock-down of CCL2 by Lentiviral 
shRNA in LLC-OVA-IKK cells resulted in abrogation of tumor regression. These 
results suggest that NF-κB is capable of promoting immune surveillance in 
tumors through increased recruitment of T cells. 
 Overall, my dissertation highlights beneficial roles of IKKβ-induced 
activation of NF-κB in two separate systems: vaccine induced immune responses 
and tumor immune surveillance.  
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Chapter 1. An introduction to innate immunity and NF-κB 
 
1.1 Innate immunity 
The immune system is comprised of a series of layered defenses. Each 
layer becomes increasingly more specific, starting from a non-specific general 
barrier such as the skin, down to receptors specific for just a few peptides in T 
cells. These various layers can be broken down into two groups: the innate 
immune system, and the adaptive immune system. Once microorganisms breech 
our physical barriers, the innate immune system becomes the first line of defense 
and is capable of initiating a rapid response. The innate immune system is 
responsible for activating the adaptive immune response, which is charged with 
generation of immunological memory. Cross-talk between these two systems is 
vital for a successful immune response. 
1.1.1. The innate immune response 
Once microorganisms break past our primary immune barriers, such as 
the skin and mucosal epithelium, the cells of the innate immune system become 
responsible for taking up the fight against the intruders. The cells that play a role 
in this fight include neutrophils, basophils, and eosinophils, collectively termed 
polymorphonuclear leukocytes (PMNs), macrophages, dendritic cells (DCs), and 
natural killer (NK) cells (1).  
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The cells in the innate immune system are capable of distinguishing self 
from non-self through pattern recognition receptors (PRRs) that recognize 
pathogen-associated molecular patterns (PAMPs) (2-4). PRRs function to 
activate complement, promote phagocytosis, and trigger the expression of 
inflammatory cytokines, chemokines, type I IFNs, and co-stimulatory molecules 
(1). 
The best-studied PRR family is the Toll-like receptor (TLR) family. TLRs 
dictate specificity through their location and recognition of specific PAMPs. For 
instance, TLR4 recognizes LPS and is located on the cell surface, whereas TLR9 
is located on the endosomal membrane and recognizes unmethylated CpG (5).  
All TLRs contain a conserved Toll-IL-1R (TIR) domain at the carboxyl 
terminus located in the cytoplasm. The TIR domain is responsible for recruiting 
adaptors to the TLR that can initiate cascades to activate transcription factors. 
Virtually all TLRs activate key transcription factors, including NF-κB and 
interferon (IFN) response factors (IRF); which play an integral role in promoting 
the adaptive immune response (6). 
While TLR family members recognize PAMPs on the cell surface or 
endosomal membrane, other PRRs recognize PAMPs found within the cytoplasm 
(4, 7, 8). Various cytoplasmic PRRs exist and they are generally organized into 
two subfamilies: nucleotide binding oligomerization domain-leucine rich repeat 
(NOD-LRR) proteins and caspase activation and recruitment domain (CARD)-
helicase proteins (4).   
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Members of the NOD-LRR family of proteins are responsible for 
recognizing bacterial components within the cytoplasm. Two of the best-studied 
NOD-LRR proteins, NOD1 and NOD2, are also capable of activating NF-κB for 
the induction of pro-inflammatory cytokines (8, 9). Proteins in this family combine 
to form macromolecular complexes called inflammasomes that recognize 
danger-associated molecular patterns and initiate an inflammatory response.   
The CARD-helicase proteins are responsible for recognizing dsRNA 
produced by viruses in the cytoplasm (10). Two members of this family include 
retinoic acid-inducible protein I (RIG-I) and melanoma differentiation-associated 
gene 5 (MDA5). These closely related proteins are activated by dsRNA produced 
by viruses and association with the adaptor protein interferon β promoter 
stimulator 1 (IPS-1) results in downstream activation of the NF-κB and IRF 
transcription factor families (4, 11, 12).  
During an infection, ligation of PRRs on resident leukocytes or viral 
infected cells results in the production of inflammatory chemokines.   
Chemokines function to recruit additional leukocytes, such as neutrophils and 
macrophages, to the area to initiate an inflammatory response and phagocytose 
necrotic cell debris or microbes (13). Chemokines are also responsible for 
bringing T cells into contact with dendritic cells to either initiate an adaptive 
immune response, in the case of infection, or to initiate tolerance, in the case of 
self antigens (14). Our lab, and others, have shown that the transcription factor 
NF-kB is responsible for the activation of many chemokines, such as CXCL1, 
CXCL2, IL-8, CXCL10, CCL2, and CCL5 (15-17). 
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1.1.2. Dendritic cells: Linking innate and adaptive immunity 
As mentioned above, the innate immune system consists of several 
different cells: neutrophils, basophils, and eosinophils, macrophages, dendritic 
cells (DCs), and natural killer (NK) cells (1).  
Natural killer cells are unique among innate immune cells because they 
are capable of directly lysing cells by releasing perforin and granzyme once they 
are activated by type I IFN and interleukin (IL-12) (18). Neutrophils and 
macrophages function as phagocytes and are capable of engulfing and killing 
microbial pathogens.  A second function of macrophages includes recognition of 
PAMPs (discussed above) and secretion of cytokines and chemokines to initiate 
inflammation. Like macrophages, DCs also recognize PAMPs; however, unlike 
macrophages, DCs are the only professional antigen presenting cell (APC) 
capable of activating naïve T lymphocytes (19-22). This unique ability makes 
DCs an important bridge between the innate immune response and the adaptive 
immune response. 
Immature DCs (iDCs) act as watchdogs of the innate immune system. 
They constantly patrol peripheral tissues sampling antigens. In the immature 
state, they express low levels of major histocompatibility complex (MHC) and co-
stimulatory molecules, but are highly phagocytic.  
In the absence of danger signals, iDCs are responsible for inducing 
peripheral tolerance to self antigens (23). When danger signals are initiated 
through bacterial or viral products, iDCs process pathogen antigens and express 
them in complex with MHC molecules on the cell surface. These activated iDCs 
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then undergo maturation (19-21). Mature DCs migrate to the lymph nodes, 
increase the expression of co-stimulatory molecules (CD40, CD80, CD86), 
secrete inflammatory cytokines and up-regulate MHC-peptide complexes on their 
surface. Once DCs arrive at the lymph nodes, T cells can be fully activated. 
Activation of T cells by DCs is a three step process. First, T cell receptors (TCR) 
must recognize the MHC:peptide complex presented. Second, co-stimulatory 
molecules on the APC (CD80 and CD86) must bind CD28 expressed on the T 
cell. Finally, the APC must secrete cytokines to direct the maturation of the T 
cells (19, 20, 22, 23). Previous work in our lab has shown that the transcription 
factor NF-κB plays an integral role in the activation of T cells by DCs. NF-κB is 
required for expression of costimulatory molecules as well as pro-inflammatory 
cytokines produced by DCs (24). 
 
1.2. An introduction to NF-κB 
As a main regulator of many immunological processes, the transcription 
factor NF-κB has garnered the attention of many researchers in the past few 
decades. Since its discovery in 1986, over 40,000 articles have been published 
on the family. As the name suggests, it was first discovered as a protein in the 
nucleus of B cells that binds kappa light chain enhancer sequences (25). Since 
its initial discovery, research has shown that NF-κB is ubiquitously expressed 
and is capable of activating a wide range of genes with varying functions, from 
activation of the immune response to inhibition of apoptosis (26, 27) Due to its 
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broad and varied functions, NF-κB has been found to play a role in a myriad of 
human diseases, from autoimmunity to cancer (28-31). 
1.2.1. The NF-κB family 
The NF-κB family is comprised of 5 transcription factors: RelA (p65), RelB, 
cRel, NF-κB1 (p105/p50), and NF-κB2 (p100/p52) (Figure 1.1). All five members 
contain a highly conserved rel homology region (RHR) as well as a DNA binding 
domain (DBD) that allows DNA binding as well as dimerization with other family 
members and binding of the inhibitors of κB (IκB) (32). The active transcription 
factor exists as a dimer that is sequestered in the cytoplasm by inhibitors. 
Three members of the family, RelA, RelB, and cRel, contain a 
transactivation domain on their carboxyl terminus and are capable of activating 
transcription when released from their inhibitors. Although these three factors are 
highly homologous, they have functional specificity, highlighted in previous 
genetic knockout studies (24, 33-36).  
NF-κB1/p50 and NF-κB2/p52 have a transrepression domain instead of a 
transactivation domain; therefore they cannot activate transcription unless 
partnered with one of the other three family members. These two proteins must 
be processed through proteasomal degradation of their precursors (p105 and  
p100) before they can become activated. Homodimers of p50 or p52 typically act 
as repressors of transcription (37).  
  7 
Figure 1.1. The mammalian NF-κB and IκB families and IKK subunits. 
Slashes show cleave site on p100 and p105 to generate p52 and p50. RHD: 
rel-homology domain. TD: transactivation domain. ARM: ankyrin repeat 
motif. KD: kinase domain. LZ: leucine zipper. HLH: helix-loop-helix. CC: 
coiled-coil. Zn: zinc finger. 
RelA 
cRel 
RelB 
p100/p52 
p105/p50 
IκBα 
IκBβ
IκBγ
IκBε
Bcl-3 
IκBζ
IκBNS
IKKα/β 
IKKγ 
RHD TD 
ARM 
KD LZ HLH 
CC1 CC2 Zn 
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1.2.2. Two pathways of activation 
Activation of NF-κB can occur through two general pathways: the classical 
(Figure 1.2), and the alternative pathway (Figure 1.3). In a resting cell, NF-κB is 
sequestered in the cytoplasm by the inhibitors of kB (IκB). These proteins, along 
with NF-κB1 and NF-κB2, contain ankyrin repeat motifs (ARMs) that bind the 
RHR of NF-κB proteins. This binding masks the nuclear localization sequence, 
which sequesters NF-κB in the cytoplasm (38-40). Upon stimulation, NF-κB is 
released from IκB through activation of the IκB kinase (IKK) complex. Activation 
of the classical or the alternative pathway of NF-κB is dependent on the 
presence or absence of IKKγ (27, 41-43). 
1.2.2a. The classical pathway 
The classical pathway (Figure 1.2) is activated by stimuli such as ligation 
of TLRs, TNFR, or IL-1R and typically results in the activation of p50, RelA, 
and/or cRel and induction of inflammatory cytokines and chemokines such as IL-
1β, TNFα, IL-6, IL-8, and KC (17). The IKK complex responsible for activation of 
the classical pathway is composed of the regulatory subunit IKKγ and two 
catalytic subunits, IKKα and IKKβ (44, 45) (Figure 1.1).  
Upon stimulation, IKKβ is phosphorylated on serines 177 and 181  
downstream of MAPK pathways and activates IKKβ allowing phosphorylation of  
IκB (46, 47). Phosphorylation of IκBα on serines 32 and 36 mark it for 
ubiquitination by the E3 ligase, β-TrCP/SCF and subsequent degradation by the 
26S proteasome. Once IκB is released, NF-κB is free to translocate to the  
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RelA 
p50 
RelA 
p50 
IκBα 
IKKβ 
TNFR, TLR, IL-1R 
IKKγ 
IKKα 
Phos 
RelA 
p50 
IκBα 
β-TrCP 
IκBα 
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Nuclear 
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transcription 
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Ub 
Figure 1.2. The core classical NF-κB pathway. Extracellular stimuli 
activate various pathways leading to the phosphorylation of IKKβ in the 
classical IKK complex. IKKβ phosphorylates IκB resulting in its 
ubiquitination by β-TrCP and degradation by the 26S proteasome. 
Freed NF-κB dimers, shown here as p50/RelA, translocate to the 
nucleus, bind κB sites and initiate gene transcription. Phos: phosphate, 
Ub: ubiquitin. 
  10
nucleus (26, 27, 37, 48). My research focused on the use of constitutively active 
IKKβ for activation of NF-κB in the immune response. IKKβ will be discussed 
further in section 2.3. 
1.2.2b. The alternative pathway 
The alternative pathway (Figure 1.3) is most commonly activated in 
response to members of the TNF superfamily, such as lymphotoxin β (49-51), 
CD40 (52), and B cell activating factor (BAFF) (53). Its activation is dependent on 
IKKα phosphorylation of NF-κB2/p100. This results in partial degradation of p100 
to the active form, p52 and allows the p52/RelB complex to translocate to the 
nucleus (54, 55). The alternative pathway plays a part in adaptive immunity 
through its role in lymphoid organogenesis (34, 56, 57). 
1.2.3. IKKβ 
 As discussed in section 2.2.1, the classical pathway of NF-κB activation 
hinges on phosphorylation of IKKβ. IKKβ was first discovered in 1997 (44) when 
it was teased out of the IKK signalosome identified in the previous year (58). The 
crystal structure of IKKβ was characterized in 2011 and differs somewhat from 
the accepted predicted structure (46, 59). Both the predicted and the crystalized 
structure of IKKβ contain a kinase domain on the amino terminus, and a NEMO 
(IKKγ) binding domain (NBD) on the carboxyl terminus; however, the crystal 
structure identif ies a ubiquit in-l ike domain (ULD) and an α-hel ical 
scaffold/dimerization domain (SDD), which takes the place of the predicted  
leucine zipper (LZ) and helix-loop-helix (HLH) motifs. IKKβ interacts with IκBα 
through the ULD and SDD (59).  
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TRAF3 
NIK 
proteasomal 
degradation 
transcription 
Nuclear 
membrane 
p52 
RelB 
p52 
RelB 
p100 
RelB 
NIK NIK 
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IKKα IKKα 
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c-IAP1/2 TRAF3 
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Figure 1.3. The alternative NF-κB pathway. In resting cells, NIK is 
ubiquitinated by c-IAP1/2, keeping NIK levels low. Upon stimulation, c-
IAP1/2 ubiquitinates TRAF3, releasing NIK and allowing its accumulation 
and activation. Active NIK phosphorylates IKKα and IKKα can then 
phosphorylate p100, resulting in its processing to p52. Free p52/RelB can 
the translocate to the nucleus to induce target gene transcription. Phos: 
phosphate. Ub: ubiquitin. 
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 Despite the discrepancy between the predicted and crystal structures, 
activation of IKKβ still requires phosphorylation of serines 177 and 181 within the 
kinase domain. How the phosphorylation of IKKβ occurs is still under discussion. 
The crystal structure of IKKβ, combined with knowledge garnered from previous 
crystal structures of IKKγ suggest that higher order oligomerization is responsible 
for trans-autophosphorylation (59). Mutation of serines 177 and 181 to glutamic 
acid produces a constitutively active form of IKKβ (CA-IKKβ). CA-IKKβ is 
sufficient for activation of classical NF-κB subunits (46); as such, it is a powerful 
tool for studying the activation of NF-κB in a variety of settings. Here, we have 
used CA-IKKβ to examine the role of IKKβ-induced NF-κB activation in a vaccine 
setting as well as in a tumor-induced immune response. 
 
1.3. The role of NF-κB in vaccine-induced immunity 
One of the many beneficial roles of NF-κB includes the induction of 
cytokines necessary to activate the adaptive immune response. During an 
infection, microbial adjuvants are recognized by dendritic cells (DCs) through 
pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) (4, 60, 
61). TLR ligation results in the activation of key transcription factors, including 
NF-κB and interferon response factors (IRFs) (62).  
It is widely believed that induction of a strong innate inflammatory 
response potentiates an adaptive immune response. In the case of a successful 
vaccine, microbial adjuvants also activate NF-κB and IRFs (63). This combined 
activation is responsible for the induction of the active form of IL-12 that can push 
  13
the immune response towards Th1-biased activation necessary for cell-mediated 
immunity (64); however, the individual roles of these transcription factors remains 
unclear.  
Despite successes in limiting infectious diseases, vaccines for non-
infectious diseases have fallen short. In the case of cancers, prophylatic or very 
early treatments have proven successful; yet this does not help the majority of 
cancer patients who typically present with well-established tumors. As such, a 
major goal of current immunotherapy is the development of strategies to treat 
established tumors (65-67). Before this can be done, a better understanding of 
what makes a successful vaccine is necessary. 
One of the most common viral vectors used for immunotherapy are non-
replicating adenoviruses (68-71). These viruses are in use in the clinic as stand-
alone agents as well as viral vectors for DC vaccines (66, 71). These vectors are 
one of the most efficient vehicles for delivering genetic material to DCs with 
limited cellular toxicity. In DCs, adenoviral vectors induce maturation via an NF-
κB-dependent pathway (72) and type I IFN signaling (73). 
In chapter 2, we use an adenoviral vector to define the role of IKKβ-
induced activation of NF-κB on the immune response to a virally encoded 
antigen. This approach gives us a clinically relevant model to examine and define 
the role of other activators of NF-κB and other transcription factors in a similar 
setting. 
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1.4. NF-κB in cancer 
Very generally, cancer can be defined as uncontrolled cell growth. More 
specifically, Hanahan and Weinberg classified six hallmarks of cancer within the 
cell that dictate malignant growth. These alterations are: self-sufficiency in growth 
signals, insensitivity to anti-growth signals, evasion of programmed cell death 
(apoptosis), limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis (74). Inflammation has been suggested as a seventh 
hallmark of cancer (75-77).  
Upregulation of NF-κB is present in many cancers, including lung cancer 
(78), melanoma (79), multiple myeloma (80), breast cancer (81), colorectal 
cancer (82), and lymphoma (83). NF-κB has been shown to play a role in at least 
some of the hallmarks of cancer, including self-sufficiency in growth signals, 
evasion of apoptosis, sustained angiogenesis, and invasion and metastasis (78, 
79, 83-87). One of the most obvious links between NF-κB and cancer is the 
inhibition of apoptosis (88). In a normal cell, NF-κB regulates apoptosis by 
targeting genes such as Bcl-xL, inhibitors of apoptosis (IAPs), and c-FLIP.  
A link between inflammation and cancer has been suspected since the 
19th century when Virchow noted that inflammatory cells were present in tumor 
biopsies from patients (89). Prolonged inflammation, as well as exposure to 
carcinogens and inflammatory agents increase the risk of cancer (90-92). This 
link between inflammation and cancer has led many researchers to study the role 
of NF-κB in the tumor environment (31, 93-95).  
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NF-κB plays a role in the recruitment of tumor-promoting inflammatory 
cells, such as neutrophils and macrophages; however, NF-κB can also activate T 
cells and promote T cell-mediated tumor suppression (30). How can these two 
seemingly opposing functions of NF-κB be reconciled? Are they present in the 
same tumor, and what determines whether NF-κB activation in the tumor is good 
(immune promoting) or bad (tumor promoting)? Many questions about the 
function of NF-κB in immunogenic tumors still remain to be answered. In chapter 
3, we attempt to shed a little light on this subject. 
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Chapter 2. IKKβ-induced inflammation impacts the kinetics but not the 
magnitude of the immune response to a viral vector 
 
2.1. Abstract 
Microbial adjuvants in vaccines activate key transcription factors, including 
NF-κB and interferon response factors (IRFs). However, the individual role of 
these transcription factor pathways in promoting adaptive immunity by adjuvants 
is not clear. It is widely believed that induction of a strong inflammatory response 
potentiates an adaptive immune response. In this study, we sought to determine 
whether activation of the pro-inflammatory inhibitor of κB kinase IKK) canonical 
NF-κB pathway promoted vaccine-induced immune responses. An adenovirus 
expressing constitutively-activated IKKβ (AdIKK) induced robust DC maturation 
and high expression of key cytokines compared to a control virus. In vivo, AdIKK 
triggered rapid inflammation after pulmonary infection, increased leukocyte entry 
into draining LNs, and enhanced early antibody and T-cell responses. Notably, 
AdIKK did not influence the overall magnitude of the adaptive immune response.  
These results indicate that induction of inflammation by IKKβ/NF-κB in this 
setting impacts the kinetics but not the magnitude of adaptive immune 
responses. These findings therefore help define the individual role of a key 
pathway induced by vaccine adjuvants in promoting adaptive immunity.  
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2.2. Introduction 
 Despite the tremendous success of vaccines in limiting the spread of 
infectious diseases, the underlying mechanisms through which successful 
vaccines work are only beginning to be understood. A central focus of current 
research is to define innate immunity mediators that can function as adjuvants to 
enhance protective adaptive immunity (96). The discovery and utilization of novel 
adjuvants can be instrumental in enhancing vaccine efficacy against infectious 
agents and cancer (96, 97). Mammalian PRRs, including TLRs, induce 
intracellular signaling in response to a plethora of microbial agents resulting in 
induction of robust innate and adaptive immune responses (4, 60, 61). Specific 
TLR ligands therefore have efficacy as vaccine adjuvants (96). Two main classes 
of transcription factors are activated by virtually all TLR ligands: NF-κB and IRF 
(4, 98). However, the individual role of these transcription factor pathways in 
promoting immune response by vaccines is not clear. NF-κB plays a key role in 
regulating expression of genes involved in inflammation, innate and adaptive 
immunity (11, 24, 43, 99-104). NF-κB activation is mediated by IKKβ  (the 
canonical pathway) and IKKα (the non-canonical pathway), both of which are 
regulated by NIK (17, 41, 105, 106). The goal of this study was to specifically 
define the role of the IKKβ canonical pathway in promoting vaccine-induced 
immune responses. We tested this in the context of an adenovirus vector, which 
are in clinical use as stand-alone vaccines (69, 70) and as antigen-expressing 
vectors for DCs (107).   
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2.3. Methods 
2.3.1. Mice  
 Six to 8-week-old C57BL/6 mice were purchased from the National 
Cancer Institute (Frederick, MD). Six to 8-week-old Balb/C mice were purchased 
from Harlan Laboratories (Indianapolis, IN). OT-1 and OT-II mice were 
purchased from Jackson Laboratories (Bar Harbor, ME) and were bred at our 
animal facility. Mice were housed at the Comparative Medicine Facility at the 
Moffitt Cancer Center and Research Institute. p50-/-cRel-/- and RelA-/- have 
been described previously and were bred in-house (108). IFNAR-/- mice were 
kindly provided by Dr. Esteban Celis (Moffitt Cancer Center). NF-κB-luciferase 
mice were kindly provided by Dr. Noreen Luetteke (Moffitt Cancer Center). All 
colonies were maintained under specific pathogen free conditions. All 
experiments were performed following the guidelines of the Moffitt Cancer Center 
and the University of South Florida Institutional Animal Care and Use Committee. 
2.3.2. Cell culture 
 
293T cells were cultured in DMEM/10% FBS supplemented with 2 mM L-
glutamine and antibiotics. AD-293 cells were purchased from Stratagene (Santa 
Clara, CA) and were cultured in 293T medium supplemented with 1 mM sodium 
pyruvate.  
Bone marrow-derived dendritic cells (BMDC) were made from BM 
suspensions flushed from femurs and tibias of mice. Briefly, cells were cultured in 
24-well plates in RPMI-1640 supplemented with 5% fetal bovine serum, 
  19
antibiotics, L-glutamine, and 2-ME in the presence of supernatant (3% vol/vol) 
from J558L cells transduced with murine GM-CSF at a density of 1x106 cells/ml. 
DC clusters were harvested after 6 days of cultures and transferred to new 24-
well plates at a density of 1-2x106 cells/ml. DC generated were >95% CD11c+. 
For antigen stimulation, DC were pulsed with OVA peptide (SIINFEKL) overnight 
prior to infection. For injection, DC were harvested 48h after infection and 
injected subcutaneously or intravenously. 
 Human peripheral blood mononuclear cells (PBMCs) were isolated 
normal donor buffy coats (Florida Blood Services) as described (109) with minor 
changes. Cells were cultured at 4-5.5x106 cells/ml in complete medium 
supplemented with 5 ng/ml of GM-CSF and IL-4. Additional growth factors were 
added on day 3 and monocyte-derived dendritic cells (MoDCs) were harvested 
on day 5.  
2.3.3. Adenovirus production and infection 
Replication deficient AdGFP and AdIKK were purchased from Vector 
Biolabs. AdIKK was produced by cloning IKKβEE into the DUAL-GFP-CCM 
shuttle vector. Adenovirus stocks were amplified by serial culture in AD-293 cells. 
Virus was harvested from AD-293 cells using 4 freeze-thaw cycles in a dry 
ice/ethanol bath and a 37ºC water bath with vortexing between each cycle. Virus 
was purified and concentrated via CsCl density centrifugation after 3-4 rounds of 
amplification. Virus titers were determined using QuickTiter™ Adenovirus Titer 
Immunoassay Kit (Cell Biolabs, San Diego, CA) according to manufacturer’s 
instructions. All purified virus stocks were tested for the presence of endotoxin 
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using the Limulus Amebocyte Lysate Assay with a sensitivity of 0.03 EU/ml 
(Associates of Cape Cod, East Falmouth, MA) using 10-fold serial dilutions of the 
virus. All stocks were negative for endotoxin at the 1:100 dilution. 
HEK-293T cells were infected with adenovirus for 48 hours. BMDCs were 
infected with AdIKK or AdGFP on day 7 of culture for 48 hours. MoDCs were 
infected on day 5 of culture at an MOI of 500 in a minimal volume for 3 hours with 
occasional shaking, then cells were plated and cultured for 48 hours prior to 
analysis. Mice were given adenovirus subcutaneously in four sites for each 
mouse: each flank, tail base and scruff, or intratracheally. Intratracheal 
administration was performed under anesthesia with 3-5% Isoflurane. Mice were 
secured in a supine position on an incline of 30-45º, and the larynx was 
visualized with an otoscope. Upon visualization, 50 µl of virus was administered 
into the trachea using a catheter. Mice were euthanized by CO2 inhalation. 
2.3.4. Flow cytometric analysis 
Uninfected (PBS), AdGFP, and AdIKK infected cells were collected and 
incubated in PBS/0.5% bovine serum albumin with anti-CD16/CD32 for five 
minutes at room temperature (RT) to inhibit Fc binding of antibodies. Then cells 
were stained with antibodies to CD11c-, B7.1-, B7.2, MHC I (H2K)-, MHC II (IA)- 
or ICAM 1-PE for 20 minutes on ice. All mouse and human antibodies were 
purchased from BD Biosciences-Pharmingen (San Diego, CA). Human MoDC 
were gated on Lin negative, HLA-DR positive populations. Flow cytometric 
analysis was performed on an LSR II cytometer (BD Biosciences, San Jose, CA). 
Aggregates and dead cells were excluded from analysis (110). Data were 
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acquired using CellQuest software (BD Biosciences, San Jose, CA) and 
analyzed using FlowJo software (Tree Star, Ashland, OR). 
2.3.5. T cell proliferation 
CD8 T cells were purified from OT-I transgenic mice by negative selection 
using antibodies to CD4, CD11b, CD11c, CD19, CD45R, CD49b, CD105, Anti-
MHC-class II, and Ter-119 according to the manufacturer’s instructions (Miltenyi 
Biotec, Auburn, CA). DC were pulsed with OVA (257-264) peptide (SIINFEKL) 
overnight and then infected with AdGFP or AdIKK for 48 hours. CD4 T cells were 
purified from OT-II transgenic mice by negative selection using antibodies to 
CD8a, CD11b, CD11c, CD19, CD45R, CD49b, CD105, Anti-MHC-class II, and 
Ter-119 according to the manufacturer’s instructions. DC were pulsed with OVA 
(323-339) peptide overnight and then infected with AdGFP or AdIKK for 48 
hours. DC were then co-cultured with OT-I CD8 T cells or OT-II CD4 T cells and 
proliferation was measured by 3H-thymidine incorporation as previously 
described (111) 
2.3.6. Tissue histology and luciferase imaging 
For histology, lungs were removed, inflated with 10% formalin, sutured 
and fixed in formalin for at least 18 hours. Sutures were removed and lungs were 
embedded in paraffin blocks. Lung sections were examined after hematoxylin 
and eosin staining. Mediastinal lymph nodes were embedded in Tissue Tek OCT 
compound (Sakura Fintek, Torrance, CA), and stained with hematoxylin and 
eosin. Lymph nodes were imaged on an Aperio ScanScope XT Automated Slide 
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Scanner (Vista, CA). NF-κB activation in the lungs of NF-κB luciferase mice was 
determined as previously described (112) with changes. Ten minutes after D-
luciferin was injected, mice were euthanized by CO2 inhalation and lungs were 
removed for imaging. Imaging was completed within 15 minutes after tissue 
harvesting on a Caliper Ivis 200 (Caliper Life Sciences, Hopkinton, MA). 
2.3.7. Western blotting and electrophoretic mobility shift assays (EMSA) 
Protein was prepared from whole cell or cytoplasmic extracts and Western 
blots were performed according to standard protocols. Rabbit anti-human IKKβ 
was purchased from Cell Signaling Technology (Boston, MA) and anti-actin-HRP 
and anti-rabbit-HRP was purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). To detect NF-κB activity, nuclear protein was extracted and EMSA was 
performed. Briefly, cells were washed in PBS then suspended in CE buffer 
(10mM HEPES (pH7.9), 10mM KCl, 0.1mM EDTA, 0.3% NP-40, and 1x Protease 
inhibitors) for 5 min. at 4°C, then centrifuged for  5 min at 1600xg. The 
supernatant (cytoplasmic extract) was removed and the remaining pellet was 
washed in CE buffer without NP-40. Finally the pellet was suspended in NE 
buffer (20mM HEPES (pH7.9), 0.4M NaCl, 1mM EDTA, 25% glycerol) and 
incubated on ice for 10 minutes with intermittent vortexing. The supernatant 
(nuclear extract) was collected after centrifugation (16,000xg for 5 min). To 
detect NF-κB activity, the following hairpin oligonucleotide was used as a probe: 
GAGAGGGGATTCCCCGATTACCTTTCGGGGAATCCCCTCT. The probe was 
annealed and end-labeled with Gamma-ATP using T4 polynucleotide kinase 
according to the manufacturer’s instructions (New England Biolabs). Labeled 
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probes (25,000cpm/rxn) were incubated with nuclear extracts, NF-κB Binding 
Buffer (50mM Tris (pH7.6), 250mM NaCl, 2.5mM EDTA, 5mM DTT, 1mg/mL 
BSA, 25% Glycerol) and 1ug poly-dI:dC for 20 min at room temperature and 
separated on a 10% non-denaturing polyacrylamide gel with 0.25X TBE running 
buffer. The gel was dried at 80ºC for 2 hours and then exposed to film overnight 
at –80ºC.  
2.3.8. RNase protection assay (RPA) and qPCR 
RNA was purified using Trizol® Reagent (Invitrogen, Carlsbad, CA) 
following the manufacturer’s instructions for RPA. To detect mRNA expression of 
cytokines in DC, RPA probe sets hCK2b, mCK2b and mCK3b (BD Pharmingen, 
San Diego, CA) were used. For qPCR, RNA was purified from culture using the 
RNEasy kit from Qiagen (Valencia, CA) according to the manufacturer’s protocol 
including the on-column DNase digestion. Lung tissue was homogenized in a 
bead beater (BioSpec, Bartlesville, OK) prior to extraction by adding 60 mg of 
lung tissue to 1.2 ml Buffer RLT + 2-ME (Qiagen RNEasy kit) and filling a 2.0 ml 
tube with 1.0 mm glass beads. Samples were subjected to 3-4 50-second 
homogenizations on the bead beater. RNA samples were reverse-transcribed 
and then subjected to quantitative PCR analysis in an Applied Biosystems 
7900HT Sequence Detection System (Carlsbad, CA) with SYBR Green I Master 
Mix (Applied Biosystems, Carlsbad, CA) using gene-specific primers. Primer 
quality was validated by checking for a single dissociation curve. All samples 
were run in triplicate and were normalized to β-actin.  Primers used for qPCR are 
listed in Table 2.1. 
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Table 2.1. RT-PCR primer list. Primers were used for RT-PCR in mouse lung 
cells and BMDC. 
Gene Forward Primer Reverse Primer 
β-actin 5’-ATGGAATCCTGTGGCATCCAT-3’ 5’-CCACCAGACAACACTGTGTTGG-3’ 
IFNβ 5’-AGCTCCAAGAAGGACGAACAT-3’ 5’-GCCCTGTAGGTGAGGTTGATCT-3’ 
IL-6 5’-CTGCAAGAGACTTCCATCCAGTT-3’ 5’AGGGAAGGCCGTGGTTGT-3’ 
TNFα 5’-AGCCGATGGGTTGTACCTTGTCTA-3’ 5’-TGAGATAGCAAATCGGCTGACGGT-3’ 
IL-12p35 5’-ACCTGCTGAAGACCACAGATGACA-3’ 5’-TAGCCAGGCAACTCTCGTTCTTGT-3’ 
IL-12p40 5’-ATGTGGGAGCTGGAGAAAGACGTT-3’ 5’-ATCTTCTTCAGGCGTGTCACAGGT-3’ 
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2.3.9. ELISA and ELISpot assays 
Peripheral blood was collected from mice at D9 and/or D21 after 
adenovirus administration via submandibular puncture and serum was collected. 
Anti-GFP IgG ELISAs were performed as previously described (68). Relative 
amounts of anti-GFP IgG were calculated by creating a linear regression model 
using two-fold serial dilutions of GFP-positive serum. The relative difference of 
each sample OD450 measurement was determined by best-fit curve. GFP 
protein was purchased from Clontech Laboratories (Mountain View, CA). Anti-
mouse IgG-HRP was purchased from Jackson ImmunoResearch Laboratories 
(West Grove, PA). For detection of CD8 T cells secreting IFN-γ, enzyme-linked 
immunosorbent spot (ELISpot) assays were performed as described (113). 
Briefly, CD8 T cells were purified from whole splenocytes of mice by positive 
selection using anti-CD8 coated magnetic beads (Miltenyi Biotec, Auburn, CA). 
Whole draining lymph nodes from mice were mechanically disrupted and passed 
through a 40 µm mesh filter to produce a single cell suspension. Mouse lungs 
were processed as previously described (114) and the T cell enriched population 
was used. Responder (CD8, lymph node or enriched lung) cells were incubated 
at different concentrations per well, together with 1x105 stimulator cells (unpulsed 
or peptide pulsed cells). EL4 cells were pulsed with the OVA peptide SIINFEKL 
for OVA-specific ELISpots and P815 cells pulsed with the GFP peptide 
HYLSTQSAL for GFP-specific ELISpots. Cells were cultured for 24 hours at 37ºC 
and spots (IFN-γ producing cells) were developed. Purified anti-mouse IFN-γ 
(capture) antibodies, biotinylated anti-mouse IFN-γ (detection) antibodies and 
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streptavidin-HRP antibodies were purchased from eBioscience (San Diego, CA). 
AEC detection substrate was purchased from BD Pharmingen (San Diego, CA). 
Spot counting was done with an AID EliSpot Reader System (Autoimmun 
Diagnostika GmbH, Strassberg, Germany). 
2.3.10. Statistical analysis 
All figures represent results from at least two independent experiments. 
Where appropriate, results are expressed as mean +/- SEM. 
 
2.4. Results  
2.4.1. Constitutively-active IKKβ induces maturation of DCs and induction 
of cytokines 
IKKβ is the primary activator of NF-κB p50, RelA (p65) and cRel subunits 
in response to most stimuli (17, 27, 41, 102). Mutation of serines 177 and 181 to 
glutamic acid (IKKβEE) locks IKKβ into an active conformation and is sufficient 
for activation of NF-κB (44, 46) We generated a replication-deficient adenovirus 
type 5 that expresses IKKβEE (AdIKK) and GFP using dual CMV promoters (Fig 
2.1A). HEK-293T cells infected with AdIKK showed high IKKβ expression and 
nuclear NF-κB translocation compared to an adenovirus that only expresses 
GFP (AdGFP) (Fig. 2.1B).  
Dendritic cells are the main cellular link between innate and adaptive 
immunity (22). As such, they can play an integral part in successful vaccine-
induced immunity. They have the ability to react directly to TLR stimulation and 
subsequently activate T cells and the adaptive immune system through direct  
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Figure 2.1. Impact of AdIKK infection on murine and human dendritic cells. (A) 
Depiction of the DUAL-GFP-CCM shuttle vector used to create AdGFP and AdIKK. 
(B) Western blot showing IKKβ expression in HEK-293T cells uninfected (UI) or 
infected with AdGFP or AdIKK (MOI=5 or 20, 48h) (left), EMSA showing nuclear 
expression of NF-κB in HEK-293T cells uninfected, infected with AdGFP or AdIKK 
(MOI=5, 48h), or treated with TNFα (20 ng/ml, 2h). (C) Western blot showing IKKβ 
expression in murine BMDC uninfected or infected with AdGFP or AdIKK (MOI=200, 
48h). (D) FACS analysis of maturation markers on murine BMDC after infection with 
AdGFP or AdIKK (MOI=200, 48h). Uninfected: shaded, AdGFP: solid black line, 
AdIKK: dotted line. (E) FACS analysis of human MoDC after infection with AdGFP or 
AdIKK (MOI=500, 48h) or treatment with LPS (10 ng/ml, 16h). Uninfected: shaded, 
AdGFP: solid black line, AdIKK: dotted line, LPS: dashed line. Results are 
representative of at least two independent experiments. GFP: AdGFP. IKK: AdIKK. 
TNF: TNFα 
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interaction with cells and cytokine production. Infection of murine BM-derived 
DCs (BMDCs; generated as described (24)) with AdIKK induced high IKKβ within 
48 hours (Fig 2.1C). Maturation of BMDC was also induced by AdIKK infection 
via increased expression of key T-cell stimulatory molecules CD80, CD86, MHC 
class II (I-Ab) and ICAM-1 shown by FACS (performed as described (24)). 
Importantly, both AdIKK and AdGFP led to similar levels of GFP expression 
following BMDC infection (Fig 2.1D). Infection of human MoDC with AdIKK also 
resulted in increased expression of CD83 and CD86 to levels similar to those 
induced by LPS stimulation (Fig 2.1E). 
In contrast, AdIKK did not increase the expression of MHC class I (H2-Kb) 
over AdGFP infected cells (Fig 2.1D). However, AdIKK increased expression of 
IFN-β, IL-6 IL-12p40, IL-12p35 (Fig 2.2A) TNF-α, IL-1α and IL-1β (Figure 2.2B), 
and protein expression of IL-6 and IL-12 (Fig. 2.2C). Infection of human MoDC 
with AdIKK also resulted in increased expression of IL-12p35 and p40, IL-1a, IL-
1b, IL-1RA, IL-6, and IFN-γ (Fig 2.2D). While numerous signaling pathways are 
known to participate in regulating DC function, these findings indicate that 
activation of IKKβ is sufficient for robust induction of expression of key cell 
surface molecules and cytokines in both mouse and human DC.  
2.4.2. AdIKK induces the expression of both pro-inflammatory and T-cell 
stimulating cytokines through p50 and cRel 
Previous work in our lab has shown that different NF-κB subunits are 
responsible for the induction of inflammatory cytokines and T cell-activating  
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Figure 2.2. Impact of AdIKK infection on cytokine expression in dendritic cells. (A) 
RT-PCR of C57Bl/6 BMDC showing cytokine induction after infecting cells with 
AdGFP or AdIKK (MOI=200, 48h) or leaving cells uninfected (UI). Results are 
averaged from triplicate samples +/- SEM.  (B) RPA of C57Bl/6 BMDC showing 
cytokine induction after AdGFP or AdIKK infection (MOI=200, 48h). (C) RPA of 
human MoDC showing cytokine induction after AdGFP or AdIKK infection 
(MOI=500, 48h). L.E.= long exposure. (D) ELISAs showing cytokine expression in 
C57Bl/6 BMDC after infection with AdGFP or AdIKK (MOI=200, 48h). Samples were 
run in triplicate and results are reported as average +/- SEM. Results are 
representative of at least two independent experiments. GFP: AdGFP. IKK: AdIKK. 
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cytokines in DC (24). To determine which canonical NF-κB subunits were 
activated by AdIKK, we examined nuclear translocation of RelA/p65, cRel and 
p50 in murine BMDCs after infection with AdGFP or AdIKK. Translocation of all 
three subunits was increased in AdIKK-infected BMDCs compared to AdGFP-
infected BMDCs (Figure 2.3A). We next determined whether RelA, cRel, or p50 
were required for AdIKK-induced cytokine production. To this end, we used 
BMDCs deficient in RelA or p50+cRel as described (24).  Interestingly, unlike 
LPS stimulation (24), RelA was not required for the induction of IL-6 in DCs after 
AdIKK infection (Fig 2.3B). However, loss of p50 and cRel greatly decreased the 
induction of IL-6, IL-12p40 and IL-12p35 (Fig 2.3B, C). These results indicate that 
AdIKK infection predominantly activates cytokine expression through p50 and 
cRel.  
2.4.3. AdIKK infected DCs are not superior stimulators of T-cell responses 
We next examined the ability of AdIKK-infected BMDCs to activate CD8+ T 
cells. BMDCs were pulsed with ovalbumin (OVA) SIINFEKL peptide as described 
(111) followed by infection with AdIKK or AdGFP. Surprisingly, although AdIKK 
increased maturation marker and inflammatory cytokine expression, BMDCs 
infected with AdIKK were incapable of increasing proliferation of OVA-specific 
OT-1 T cells compared to AdGFP-infected or uninfected BMDCs (Fig 2.4A). This 
is consistent with previous results showing no difference in MHC I molecule 
expression on BMDC. Since AdIKK infection of BMDCs increased MHC class II 
expression compared to AdGFP (Fig 2.1D), we also examined their ability to  
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Figure 2.3. Role of classical NF-κB subunits in AdIKK responses. (A) BMDCs were 
either uninfected or infected with AdGFP or AdIKK (MOI=200, 48h). Western blot 
using BMDC nuclear extracts to detect canonical NF-κB subunits. (B, C) C57Bl/6 WT 
and (B) RelA KO BMDCs or (C) p50/cRel KO BMDCs were either uninfected or 
infected with AdGFP or AdIKK (MOI=200, 48h) and mRNA of the indicated cytokines 
was determined by RT-PCR, with the results normalized to β-actin expression levels. 
Results are representative of at least two independent experiments. UI: uninfected. 
GFP: AdGFP. IKK: AdIKK 
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induce proliferation of OVA-specific OT-II CD4+ T cells. However, no significant 
difference in the proliferation of OT-II CD4+ T cells in any group was noticed (Fig 
2.4B). Therefore, AdIKK-infected BMDCs are incapable of enhancing T cell 
activation over control BMDCs.  
We next examined the in vivo ability of AdIKK or AdGFP-infected BMDCs 
to activate and induce functional differentiation of CD8+ T cells as determined by 
IFNγ production using ELISPOT (115). Previous studies have characterized the 
response of CD8+ T cells to the H2-Kd-restricted GFP peptide HYLSTQSAL 
(116). BMDCs were infected with AdGFP or AdIKK and injected intravenously in 
mice. However, no increase in GFP-specific IFN-γ-producing CD8+ T cells was 
seen in mice injected with AdIKK-infected BMDCs compared to mice injected 
with AdGFP-infected BMDCs after 14 days (Fig 2.4C). These experiments were 
repeated using 3- or 10-fold fewer BMDCs, which were injected subcutaneously. 
The subcutaneous administration also resulted in similar CD8+ T cell activation at 
7 or 15 days after injection (data not shown). 
BMDC vaccine trials commonly use peptide pulsing to introduce antigens 
to the BMDC alone or in concert with virus infection (66). To this end, we used 
BMDC pulsed with exogenous peptide (SIINFEKL) prior to infection. 
Subcutaneous administration of pulsed and infected BMDC also showed no 
increase in OVA-specific IFN-γ-producing CD8+ T cells in mice injected with 
AdIKK-infected BMDCs compared to those injected with AdGFP-infected BMDCs 
(Fig 2.4D). Therefore, despite the substantial increase in expression of co- 
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Figure 2.4. Impact of IKK expression in BMDC on T cells. (A) BMDCs from C57Bl/6 
mice were either left untreated or pulsed with 1nM SIINFEKL overnight and then 
either infected with AdGFP or AdIKK (MOI=200, 48h) or left uninfected. 3H-
thymidine incorporation was used to measure proliferation in triplicate samples. (B) 
BMDC from C57Bl/6 mice were pulsed with 50nM OVA peptide (323-339) overnight 
and infected (MOI=250, 24h). 3H-thymidine incorporation was used to measure 
proliferation in triplicate samples. (C) Balb/C BMDCs were infected with AdGFP or 
AdIKK (MOI=500, 48h) then 1x106 cells were injected intravenously into 3 Balb/C 
mice per group. After 14 days, CD8+ T cells were isolated from pooled spleens of 3 
mice and IFN-γ production was determined by ELISPOT. (D) C57Bl/6 BMDCs were 
pulsed with SIINFEKL overnight and infected with AdGFP or AdIKK (MOI=250, 6h) 
then 5x105 cells were injected s.c. into C57Bl/6 mice. After 6.5d, T cells were 
isolated from pooled splenocytes and IFN-γ production was determined by 
ELISPOT. Results are reported from triplicate wells as mean +/- SEM. Results are 
representative of at least 2 independent experiments. 
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stimulatory molecules and T-cell stimulating cytokines, AdIKK-infected BMDCs 
are not superior T cell stimulators.  
2.4.4. AdIKK-induced inflammation impacts the kinetics but not the 
magnitude of adaptive immune response 
Inflammation is known to stimulate adaptive immunity through multiple 
mechanisms, including APC activation, increased recruitment of leukocytes to 
inflammatory sites and lymphoid tissues, and direct effects on lymphocyte 
functions.  We next determined whether potentially robust induction of pro-
inflammatory cytokines by AdIKK could affect T and B cell responses. To this 
end, we used a pulmonary infection model that has previously been shown to 
induce potent inflammation (117). We first determined in situ NF-κB activation 
using a transgenic mouse strain in which NF-κB sites drive luciferase reporter 
gene expression (118). As shown in Fig 2.5A, AdIKK, but not AdGFP, induced 
strong luciferase reporter gene expression 48 hours after lung infection. The 
luciferase expression is most intense in the central portion of the lungs because 
the virus is administered intratracheally; therefore, cells near the entrance to the 
lungs are most likely to be infected by the virus. Inflammation was evident in the 
lungs of AdIKK-infected mice as early as 48 hours after administration and its 
effects were still present at least 21 days after administration. Lungs of mice 48 
hours after AdIKK administration were markedly congested, edematous and 
infiltrated with numerous mixed inflammatory cells that formed prominent peri-
vascular and peri-bronchiolar cuffs, and persisted for at least 21 days (Fig 2.5B).  
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Figure 2.5. Impact of AdIKK on the pulmonary inflammatory response. (A) PBS 
or 1x109 IFU AdGFP or AdIKK was administered intratracheally to NF-κB-
luciferase mice. 48h after virus administration, mice were injected 
intraperitoneally with D-luciferin. 10 minutes later, mice were euthanized by CO2 
inhalation and lungs were removed for imaging on a Caliper IVIS 200. Imaging 
was completed within 15 minutes after tissue harvesting. (B) PBS or 1x109 IFU 
AdGFP or AdIKK was administered intratracheally to C57Bl/6 mice. Lungs were 
removed after 48h and H&E staining was done on formalin-fixed paraffin 
embedded sections. Original magnification: 100x (1, 2, 5-7), 40x (3, 4), 200x (8-
10). T: terminal bronchioles. AD: alveolar ducts. Scale bars for each row are the 
same. Arrows denote perivascular cuffing of inflammatory cells. (C) PBS  or 
1x109 IFU AdGFP or AdIKK was administered intratracheally to 3 Balb/C mice 
per group followed by measurement of TNFα and IL-6 expression in total lung 
homogenates by RT-PCR 2 days later. Each symbol represents RT-PCR results 
from an individual mouse, the horizontal line represents the mean +/- SEM.  
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Terminal bronchioles (TB) 21 days following AdIKK-administration had 
undergone squamous metaplasia, and were lined by multiple layers of flattened 
to elongated cells with oval nuclei and slightly basophilic cytoplasm (Figure 
2.5B.7), and alveolar septa (Figure 2.5B.10) were markedly thickened, 
hemorrhagic, infiltrated by inflammatory cells, and comprised of prominent 
bulging type II pneuomocytes, while alveolar sacs were filled with numerous 
pulmonary macrophages.  In contrast, 48 hours after AdGFP administration, 
lungs were only mildly congested and edematous. This mild inflammation 
persisted for 21 days, but no other changes were evident. In agreement with the 
above results, RT-PCR of homogenized lungs showed a 4-fold increase in the 
pro-inflammatory cytokines IL-6 and TNFα  after 48 hours in AdIKK-infected, but 
not AdGFP-infected mice (Fig 2.5C) 
We proceeded to characterize the potential effect of NF-κB driven 
inflammation on the adaptive immune response to GFP as described above. 
While there was no substantial difference in the percentage of GFP-specific T 
cells at day 9 as determined by IFN-γ ELISPOT (not shown) the total number of 
GFP-specific T cells was substantially greater in draining LN of AdIKK-infected 
versus AdGFP-infected mice (Fig. 2.6A). In addition, there was a substantial 
increase in size and total cell numbers of draining LN of AdIKK infected mice on 
day 9 after infection (Fig. 2.6B). Importantly, the relative anti-GFP IgG response 
(determined as described (119)), on day 9 was over 3-fold higher in mice that 
received AdIKK compared to mice that received AdGFP (Fig 2.6C). In contrast, 
the total LN cell numbers, the number of GFP-specific T cells (not shown), and  
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Figure 2.6. Effect of AdIKK administration on the adaptive immune response. (A) 10 
days after intratracheal virus administration, mediastinal LNs were harvested from 3-
4 mice in each of two separate experiments, pooled and total LN cells were counted. 
Total antigen-specific T-cell numbers were determined by ELISPOT in triplicate. The 
relative Ag specific CD8+ T-cell numbers are from duplicate experiments plotted as 
fold-change compared to the AdGFP (mean and SEM). (B) PBS or 1x109 IFU 
AdGFP or AdIKK was administered intratracheally to Balb/C mice. 9 days after 
administration, mediastinal lymph nodes were excised and embedded in Tissue Tek 
OCT. Hematoxylin and Eosin staining was performed on 5 um frozen sections and 
slides were imaged on an Aperio ScanScope XT Automated Slide Scanner. All 
images are captured at the same magnification. Scale bars represent 500 um. (C) 
Serum was pooled from 3 mice infected intratracheally with AdGFP or AdIKK after 9 
and 21 days. The anti-GFP IgG response was measured by ELISA. Samples were 
read in triplicate, relative antibody levels were determined by interpolation of a 
dilution curve run in parallel to the samples. Results from duplicate experiments are 
plotted as fold-change compared to the AdGFP controls (mean and SEM). (D) 
Performed as in (C) except mice were injected s.c. in four locations with a total of 
5x108 IFU AdGFP or AdIKK. Serum was collected at days 9 and 21 and an anti-GFP 
IgG ELISA was performed and analyzed as in (C). Results are representative of at 
least two independent experiments. 
C. 
D. 
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anti-GFP antibody was not different at day 21 between AdGFP and AdIKK-
infected mice (Fig 2.6C). Therefore, AdIKK impacts the kinetics but not the 
overall magnitude of an adaptive immune response.  
The patho-physiology of lungs makes them uniquely prone to induction of 
robust inflammation following encounter with noxious or infectious agents. We 
next determined if vaccination with AdIKK through alternative routes could also 
impact the kinetics of an antibody response. However, subcutaneous AdIKK 
injection had no potentiating effect on anti-GFP IgG levels on day 9 or 21 (Fig. 
2.6D) nor did it induce a visible inflammatory response. These results were also 
evident with a 10- and 50-fold reduction in the total virus injected (data not 
shown). Therefore, the impact on kinetics of the adaptive immune response 
appears to be evident only under conditions of robust inflammation, as seen in 
the lungs. In conclusion, our results indicate that IKKβ primarily functions through 
induction of strong pro-inflammatory signals that specifically enhance the kinetics 
of an immune response to a viral vector.  
 
2.5. Discussion 
Previous studies have shown that adenovirus-mediated intracellular 
expression of NIK can strongly enhance the magnitude of an adaptive immune 
response in an adenovirus vaccine setting (see below) (119). Importantly, we 
report here that IKKβ primarily impacts the kinetics but not the magnitude of T-
cell or antibody responses. The impact on kinetics is likely the result of IKKβ-
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induced cytokines such as TNFα and/or TNF family members, which are known 
to enhance lymphocyte trafficking to LNs (120). Increased presence of 
lymphocytes may therefore increase the likelihood of early activation of antigen-
specific lymphocytes. Our results suggest that IKKβ may be useful as an 
intracellular adjuvant in airway vaccines to achieve a more rapid immune 
response.   
NIK activation of IKKα can also lead to IRF3/7 activation (121, 122).  The 
increased magnitude of the immune response triggered by NIK (119) may 
therefore be mediated through combined activation of NF-κB and IRF3/7 by 
IKKβ/IKKα. However, in our hands, AdNIK did not increase expression of DC 
maturation markers and cytokines as seen with AdIKK (Fig 2.7A, B). In addition, 
AdNIK poorly induced nuclear translocation of canonical and non-canonical (p52 
and RelB) NF-κB subunits compared to AdIKK (Fig 2.7C). In contrast, both 
AdIKK and AdNIK robustly induced NF-κB subunit nuclear translocation of HEK-
293T cells (Fig 2.7D). It is presently unclear why AdNIK fails to activate NF-κB in 
BMDCs. Nonetheless, our results suggest that the main mechanism proposed by 
Andreakos, et al. (119) to explain AdNIK adjuvant function in mice (i.e., robust 
activation of NF-κB in APC), is unlikely to fully explain its immunostimulatory 
effects. Loss of NIK in mice results in structural defects of secondary lymphoid 
structures as well as impaired CD40 signaling and class switching in B cells 
(123-125). It is therefore possible that NIK-induced activation of adaptive 
immunity is mediated by profound changes in lymphoid tissue organization  
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Figure 2.7. In vitro comparison of AdIKK and AdNIK infection. (A) Expression of co-
stimulatory and maturation markers on BMDC infected with AdGFP, AdIKK, or 
AdNIK (MOI=200, 48h) as determined by FACS, Uninfected: shaded, AdGFP-
infected: solid line, AdIKK-infected: dashed line, AdNIK-infected: dotted line. (B) 
Induction of cytokines in infected BMDC (MOI=200, 48h) shown by RT-PCR, results 
normalized to β-actin expression levels and reported as mean +/- SEM. (C, D) 
Western blots of nuclear extracts showing activation of NF-κB subunits in (C) BMDC 
(MOI 200) and (D) HEK-293T cells (MOI 20) after 48h infection. E. EMSA showing 
NF-κB activation in HEK293 cells after 48h infection with indicated MOI.  Arrow 
denotes NF-κB complexes. 
UI   AdGFP AdIKK AdNIK
  RelA 
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β-Actin 
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and/or through stimulatory effects on multiple cell types. Thus, the 
immunostimulatory effects of NIK and IKKβ may be mediated by distinct 
mechanisms. Recent studies indicate that microbial agents and inflammatory 
cytokines have distinct effects on DC function, with only the former promoting 
adaptive immunity (126). Based on our results, we suggest that microbial agent-
induced activation of multiple pathways strongly promotes adaptive immunity 
while the exclusive activation of inflammatory cytokines/IKKβ has a more limited 
effect. 
Major efforts are underway to understand how successful vaccines work 
and to define novel adjuvants that can enhance protective adaptive immunity. 
While virtually all microbial adjuvants activate NF-κB and IRF pathways, their 
specific functions in promoting adaptive immunity are not clear. Our results 
indicate that IKKβ canonical NF-κB pathway-induced inflammation impacts the 
kinetics but not the magnitude of the immune response to an adenovirus-
encoded antigen. These findings therefore help define the individual role of a key 
pathway induced by vaccine adjuvants. A similar strategy can help determine 
how other major pathways, e.g., IKKα and IRF, promote adaptive immunity and 
whether their efficacy and underlying mechanisms are distinct from those 
induced by IKKβ.  
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Chapter 3. Crucial role of NF-κB in T cell mediated immune surveillance in 
murine lung cancer. 
 
3.1. Abstract 
NF-κB is constitutively activated in many tumor types and known to play a 
crucial role in suppressing cell death and enhancing tumor angiogenesis and 
metastasis. NF-κB also promotes tumor-associated inflammation characterized 
by neutrophil and macrophage presence, both of which promote tumor growth 
and invasion. Also present within the tumor microenvironment are T cells, the 
presence of which can be associated with immune surveillance and improved 
patient survival. We investigated whether in addition to known tumor promoting 
functions, NF-κB activation also promotes T cell mediated immune surveillance. 
In both primary tumors and a metastatic tumor model, we found that NF-κB 
expression in tumors rendered immunogenic through expression of Kb-OVA led 
to tumor rejection or growth suppression. Tumor growth in athymic nude mice 
was not affected by IKK, indicating regression was T cell mediated. IKK did not 
increase the overall number of T cells, nor did it make LLC-OVA cells better 
targets for T cells; it did increase recruitment of T cells to the tumor. Microarray 
results showed increases in T cell chemokines, including CCL2 and CCL5. 
Knock-down of CCL2 by Lentiviral shRNA in LLC-OVA-IKK cells resulted in 
  45
abrogation of tumor regression. These results suggest that NF-κB is capable of 
promoting immune surveillance in a subset of tumors through increased 
recruitment of T cells. 
 
3.2. Introduction 
A link between inflammation and cancer has been suspected since the 
19th century; however, we are only beginning to understand it (89, 127). One of 
the main regulators of inflammation is the Nuclear Factor-κB (NF-κB) family of 
transcription factors (32, 48, 102). The NF-κB family consists of five members 
that form homodimers or heterodimers to regulate a plethora of genes. Activation 
of NF-κB is dependent on phosphorylation of the Inhibitors of κB (IκB) by IKKβ 
(classical pathway) and IKKα (alternative pathway) (17, 41, 105, 106).  These 
two pathways are responsible for activating genes regulating varied processes, 
from inflammation and immunity to apoptosis (32, 37, 48, 88, 102, 128). As such, 
NF-κB has been shown to play a role in a number of the hallmarks of cancer 
(74), including self-sufficiency in growth signals, evasion of apoptosis, sustained 
angiogenesis, and invasion and metastasis (78, 79, 83-87). Indeed, aberrant NF-
κB expression is present in many cancers including lung cancer (78), melanoma 
(79), multiple myeloma (80), breast cancer (81), colorectal cancer (82), and 
lymphoma (83).  
 We now know that other cells present within the tumor microenvironment 
play as profound a role as intrinsic tumor mutations. NF-κB expression within the 
tumor microenvironment can promote tumor-associated inflammation 
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characterized by the presence of neutrophils and macrophages, both of which 
promote tumor growth and invasion (77, 129). Contrary to the presence of 
inflammatory cells, the presence of T cells in the tumor microenvironment is 
associated with increased patient survival and immune surveillance (130, 131). In 
this study, we expressed constitutively active IKKβ in lung tumors to induce the 
canonical pathway and determine if NF-κB expression in tumors can promote 
immune surveillance. 
 
3.3. Methods 
3.3.1. Mice 
Six to 8-week-old C57BL/6 mice were purchased from the National 
Cancer Institute (Frederick, MD). Six to 8-week-old athymic nude mice and CB6 
mice were purchased from Harlan Laboratories (Indianapolis, IN). Rag 2-/- mice 
were kindly provided by Dr. Xue-Zhong Yu (Moffitt Cancer Center). All colonies 
were maintained under specific pathogen free conditions. All experiments were 
performed following the guidelines of the Moffitt Cancer Center and the 
University of South Florida Institutional Animal Care and Use Committee. 
3.3.2. Cell culture 
Lewis Lung Carcinoma and Turin-Bologna (TUBO) cell lines were cultured 
in DMEM supplemented with 10% fetal bovine serum (FBS), antibiotics, and 
2mM L-glutamine. Human cells lines (H157) were cultured in RPMI 
supplemented with 10% fetal bovine serum (FBS), antibiotics, and 2mM L-
glutamine. 
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3.3.3. Retroviral and lentiviral transduction 
Retroviruses were prepared by transfecting HEK 293T cells with Kb-OVA, 
MiG or IKKβEE and packaging vectors as previously shown (24). Retrovirus 
transduced cells were sorted based on GFP expressing using a FACS Vantage 
sorter (BD Biosciences, San Jose, CA). Lentiviruses were prepared by 
transfecting HEK 293T cells with scrambled control pLKO.1 or pLKO.1  
expressing shRNA  specific for CCL2 (Open Biosystems) along with packaging 
vectors (24). Lentivirally transduced cells were selected for puromycin resistance.  
3.3.4. Flow cytometric analysis 
All transfected cell lines were tested for expression of inserted genes 
using FACS. MiG and IKKβ transfected lines were analyzed for GFP expression 
and viability. Kb OVA expressing cell lines were incubated with anti-CD16/CD32 
to block Fc binding, and stained with Kb OVA-phycoerytherin for 15-20 minutes 
on ice. Kb-OVA expression was analyzed as well as viability. All lines showed 
greater than 95% GFP and/or Kb-OVA expression. Antibodies were purchased 
from BD Biosciences-Pharmingen (San Diego, CA). Tetramer staining was 
completed as described with the following changes: cells were incubated for 5 
minutes at RT with Fc block and DAPI was added to cells prior to analysis for 
viability gating (132). p66 tetramer was kindly provided by E. Celis (Moffitt 
Cancer Center, Tampa, FL) and H2-Kb OVA tetramer was purchased from 
Beckman Coulter  (Brea, CA). Flow cytometric analysis was performed on an 
LSR II cytometer (BD Biosciences, San Jose, CA). Aggregates and dead cells 
were excluded from analysis (110). Data were acquired using CellQuest software 
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(BD Biosciences, San Jose, CA) and analyzed using FlowJo software (Tree Star, 
Ashland, OR). 
3.3.5. Western blotting and electrophoretic mobility shift assays (EMSA) 
Protein was prepared from whole cell or cytoplasmic and nuclear extracts 
and Western blots were performed according to standard protocols. Rabbit anti-
human IKKβ was purchased from Cell Signaling Technology (Boston, MA) and all 
other antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). To detect NF-κB activity, EMSA was performed as described in chapter 2. 
3.3.6. ELISA and ELISpot assays 
Supernatant was collected from LLC-OVA-IKK cells after 48h of culture. 
Anti-CCL2 ELISA was performed to confirm CCL2 knockdown using the Mouse 
CCL2 ELISA Ready-SET-Go® kit from eBioscience (San Diego, CA) according 
to the manufacturer’s instructions. Samples were run in triplicate.  
ELISpot assays were performed as described in chapter two with the 
following changes: T cells were isolated from splenocytes of OT-I transgenic 
mice and LLC-OVA-MiG or LLC-OVA-IKK cells were used as targets. 
3.3.7. Tumor studies 
Cells were harvested in logarithmic growth after being cultured for less 
than two weeks and washed once in injection medium (phenol-free DMEM 
supplemented with 2% FBS) and counted. 5x105 LLC cells were injected either 
subcutaneously (s.c.) (in a volume of 100 µl) in the right flank or intravenously 
(i.v.) (in a volume of 200 µl) in the tail vein. 3x105 TUBO cells were injected s.c. 
in a volume of 100 µl. Subcutaneous tumors were monitored for growth and 
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measured 2-3 times per week. Mice receiving intravenous LLC injections were 
monitored for morbidity. Mice were sacrificed when s.c. tumors reached a 
diameter of 20 mm or when they showed signs of morbidity (i.v. or s.c.). Tumor 
volume was calculated as previously described (133). 
Mice receiving TUBO cells were split into treatment and non-treatment 
groups on day 5, with a bias towards larger tumors in the treatment group. 
Immunization with p66 TriVax was performed as described on day 5 (132). The 
p66 peptide specific for TUBO cells was previously described (134). 
3.3.8. RNA analysis 
RNA was isolated using a Qiagen RNEasy kit, then reverse-transcribed 
and subjected to quantitative PCR analysis in an Applied Biosystems 7900HT 
Sequence Detection System (Carlsbad, CA) with SYBR Green I Master Mix 
(Applied Biosystems, Carlsbad, CA) using gene-specific primers. Primer quality 
was validated by checking for a single dissociation curve. All samples were run in 
triplicate and were normalized to β-actin.  
Microarray using Mouse Genome 430 2.0 Arrays was performed on 
poly(A) RNA specifically converted to cDNA and then amplified and labeled with 
biotin using the Ambion Message Amp Premier RNA Amplification Kit (Life 
Technologies, Grand Island, NY) following the manufacturer’s protocol (135). 
Hybridization with the biotin-labeled RNA, staining, and scanning of the chips 
followed the prescribed procedure outlined in the Affymetrix technical manual 
(136). Results were analyzed using Affymetrix GeneChip Operating Software 
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(GCOS) using the MAS 5.0 algorithm. Genes were considered changed if there 
was a 2-fold difference in signal compared to the control. 
3.3.9. Histology 
Mouse tumors were excised and sections were embedded in Tissue Tek 
OCT compound (Sakura Fintek, Torrance, CA) or placed in 10% formalin and 
subsequently embedded in paraffin blocks (FFPE). Frozen sections of mouse 
tumors were stained with anti-CD8 and the Rat-IgG HRP detection kit from BD 
Biosciences. Mouse lungs were insufflated in 10% formalin and paraffin-
embedded prior to H&E staining. Lung sections were imaged on an Aperio 
ScanScope XT Automated Slide Scanner (Vista, CA). 
3.3.10. Statistical analysis 
Relative tumor growth analyzed with Fisher’s Exact T test. Tetramer 
staining was analyzed using the Student’s T test with Welch’s correction. 
 
3.4. Results 
3.4.1. Critical role of IKKβ/NF-κB in T cell-induced tumor rejection  
Poorly immunogenic Lewis lung carcinoma (LLC) was rendered 
immunogenic by expression of Kb-OVA (a single polypeptide encoding H-2Kb, β2-
microglobulin and ovalbumin SIINFEKL peptide) for recognition by CD8 T cells. 
Expression of IKKβ in parental (Fig 3.1A) or LLC-OVA enhanced nuclear NF-κB, 
comprising primarily of RelA/p65, and target gene CXCL1/KC expression (Fig 
3.1B, C). However, both were substantially less than induced by TNFα (Fig 3.1B, 
C). Instead, NF-κB activity in LLC-OVA-IKK was comparable to a human lung  
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Figure 3.1. Impact of IKKβ expression on LLC cells. (A) EMSA showing nuclear 
levels of NF-κB (top) and AP1 (bottom) in LLC-MiG, LLC-IKK, or LLC-MiG cells 
treated with TNFα (B) EMSA showing NF-κB nuclear levels in LLC-OVA transduced 
with control MiG, IKK and MiG treated with TNFα for 1h and 2h as indicated.  (C) 
RT-PCR showing KC/CXCL1 expression in LLC-OVA transduced with control MiG, 
IKK and MiG treated with TNFα for 1h and 2h as indicated. Samples were run in 
triplicate and reported as mean +/- SEM. (D) EMSA showing nuclear levels of NF-
κB in LLC-OVA-MiG, LLC-OVA-IKK, or H157 cell lines. TNFα treatment: 20 ng/ml. 
Results are representative of at least two independent experiments.  
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cancer cell line harboring KRAS and p53 mutations, which are known to activate 
NF-κB (137) (Fig 3.1D). Compared to control LLC-MIG, LLC-IKK had no 
significant effect on growth of non-immunogenic LLC in syngeneic C57BL/6 mice 
(Fig 3.2A). In contrast, LLC-OVA-IKK tumors grew initially but were subsequently 
rejected (Fig 3.2B). Combined results from 3 experiments indicated that once 
tumors were perceptible, 10/11 LLC-OVA-MIG showed tumor growth while only 
3/11 LLC-OVA-IKK showed similar growth (p=0.004, Fisher’s Exact Test) (Fig 
3.2C). Importantly, a similar number of activated OVA-specific CD8 T cells were 
detected in peripheral blood of mice receiving LLC-OVA-MIG and LLC-OVA-IKK 
(Fig 3.2D) suggesting that reduced growth of LLC-OVA-IKK was not due to 
impaired T cell priming. Using a metastatic LLC model, LLC-OVA-IKK showed 
substantially fewer and smaller lung tumor foci than LLC-OVA-MIG (or LLC-MIG 
and LLC-IKK) (Fig 3.2E, F). Finally, LLC-OVA-IKK grew robustly in Rag2-/- mice 
(Fig 3.3A) and in athymic nude mice (Fig 3.3B), demonstrating a role of 
lymphocytes, and more specifically, T cells, in immune rejection of LLC-OVA-
IKK.  
We next determined the effect of NF-κB activation in vaccine induced 
responses against the breast carcinoma TUBO line, which naturally express 
Her2/neu/p66. Five days after tumor inoculation, when tumors were perceptible, 
TUBO-MiG and TUBO-IKK injected mice were split into control (no vaccine) and 
vaccine groups. Vaccinated mice received the previously characterized 
Her2/Neu/p66 TriVax (132, 138) containing the p66 peptide, polyI:C as a TLR 
agonist, and anti-CD40. TriVax-induced responses were determined in peripheral  
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Figure 3.2. Impact of IKKβ expression on LLC growth and T cell response in 
C57Bl/6 mice. (A)Tumor growth in C57Bl/6 mice inoculated s.c. with LLC-MiG and 
LLC-IKK over indicated time periods. (B) Tumor growth in C57Bl/6 mice inoculated 
s.c. LLC-OVA-MiG and LLC-OVA-IKK over indicated time periods. Each line 
represents tumor growth in a single mouse. (C) C57Bl/6 mice received s.c.LLC-
OVA-MiG or LLC-OVA-IKK and tumor growth was monitored. Relative fold increase 
in tumor volume at D21 post-inoculation compared to D4 post-inoculation. 
Combined results from 3 independent experiments are shown. (D) H2Kb-OVA 
tetramer analysis of peripheral blood on D10 from naïve mice or mice receiving 
LLC-OVA-MiG or LLC-OVA-IKK cells s.c. (E) H&E staining of lungs from mice 24 
days after receiving i.v. LLC-MiG or LLC-IKK (left) or LLC-OVA-MiG or LLC-OVA-
IKK. Scale bars: 4 mm (F) H&E staining of lungs from mice 24 days after receiving 
i.v. immunogenic LLC-OVA-MiG or LLC-OVA-IKK. Scale bars: 1 mm (top), and 200 
µm (bottom) Results are representative of lungs from 4 mice for each condition. 
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Figure 3.3. Impact of lymphocytes on immunogenic LLC tumor growth. (A, B) 
Tumor growth in (A) RAG2-/- mice or (B) athymic mice inoculated s.c. with LLC-
OVA-MiG or LLC-OVA-IKK. Results are representative of two independent 
experiments. Each line represents tumor growth in a single mouse. 
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blood (Fig 3.4A). The addition of IKK had no impact on activation of p66-specific 
T cells. Tumor growth of vaccinated TUBO-MIG and TUBO-IKK was then 
determined relative to their unvaccinated counterparts. While vaccination 
reduced growth of both TUBO-MIG and TUBO-IKK tumors, the reduction was 
significantly more pronounced in TUBO-IKK (p=0.025) (Fig 3.4B). These results 
show that NF-κB activation enhances tumor rejection in spontaneous and 
vaccine-induced T cell priming models.  
3.4.2. NF-κB induced T cell chemokine expression is crucial for tumor 
rejection 
We next investigated potential mechanism(s) of rejection of LLC-OVA-IKK.  
As shown above, rejection was unlikely to be mediated by increased numbers of 
OVA-specific CD8 T cells (Fig 3.2D) In addition, LLC-OVA-IKK were not superior 
stimulators of CD8 T cell function as determined IFN-γ production (Fig 3.5A).  We 
next examined whether NF-κB activation increases CD8 T cell recruitment in 
tumors. Immunohistochemistry to determine CD8 T cell presence within tumors 
on day 9 (i.e., prior to regression) demonstrated the presence of a small number 
of CD8 T cells in LLC-OVA-MIG tumors (Fig 3.5B). In striking contrast, IKK 
tumors showed greatly increased CD8 T cell presence as well substantial areas 
of tumor necrosis (Fig 3.5B). These results indicate that increased CD8 T cell 
recruitment may be primary reason for rejection of IKK expressing tumors.  
To identify potential T cell chemokines involved, we performed microarray 
analysis of LLC-OVA-MIG and LLC-OVA-IKK cells.  We used a 2-fold cutoff to 
identify genes regulated by IKKβ/NF-κB (Table 3.1). Microarray analysis 
identified 88 unique genes that were upregulated at least 2-fold in LLC-OVA-IKK  
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A. B. 
Figure 3.4. Impact of IKKβ expression on TUBO response to p66 TriVax.  
(A) Tetramer analysis of peripheral blood on day 10 from naïve mice or mice 
receiving TUBO-MiG or TUBO-IKK with or without TriVax vaccination. 
Vaccination given on day 5. Results are representative of at least two 
independent experiments. P value: Student’s T test with Welch’s correction. (B) 
CB6 mice received s.c. TUBO-MiG or TUBO-IKK. After 5 days, half of the mice 
in each group received p66 TriVax and tumor growth was monitored. Tumor 
growth of all mice was calculated at D21 relative to D5 and vaccinated mice 
were compared relative to their unvaccinated counterparts. Results are 
compiled from two separate experiments. P value: Fisher’s Exact Test. Results 
are plotted as a separate mouse for each point with mean +/- SEM. 
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Figure 3.5. Mechanism for T cell-induced tumor regression. ELISpot of OT-I T 
cells cultured with LLC-parental, LLC-OVA, LLC-OVA-MiG, or LLC-OVA-IKK 
tumor cells. 1x105 LLC targets/well. Samples were run in triplicate with results 
reported as mean +/- SEM. (B) C57Bl/6 mice received s.c. LLC-OVA-MiG or 
LLC-OVA-IKK. Tumors were excised at D9. Frozen sections were cut and 
stained for CD8 using IHC. Scale bars: 50x= 150 mm and 200x= 50 mm. 
Results are representative of at least two independent experiments.  
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Table 3.1. Positive impact of IKKβ on genes expressed in LLC-OVA tumor cells. 
Genes were identified as being increased over 2-fold in LLC-OVA-IKK cells 
compared to LLC-OVA-MiG cells by mircroarray. Genes are listed in order of 
decreasing fold-induction. Multiple probe sets for the same genes are listed and 
a total of 88 unique genes are upregulated in LLC-OVA-IKK cells compared to 
LLC-OVA-MiG cells. 
    Experiment 1 Experiment 2   
Gene Symbol Probeset Fold Change Fold Change Average 
C3  1423954_at 184.83 90.55 137.69 
Mmp9  1448291_at 95.62 18.34 56.98 
Casp4  1449591_at 85.50 17.08 51.29 
Traf1  1423602_at 15.39 60.79 38.09 
Mmp9  1416298_at 56.08 19.51 37.80 
Tmem176a  1425603_at 14.97 28.48 21.72 
LOC100416221  1441746_at 31.33 8.32 19.83 
Gdpd5  1424150_at 5.39 33.77 19.58 
Saa3  1450826_a_at 23.19 9.45 16.32 
Pcdh1  1452294_at 26.00 6.55 16.28 
Spt1  1448168_a_at 28.67 2.94 15.80 
A4galt  1455338_at 22.82 7.45 15.13 
Bcl3  1418133_at 4.11 26.11 15.11 
Nfkbie  1458299_s_at 20.27 9.16 14.71 
Fam84a  1425452_s_at 19.89 8.35 14.12 
Bicd1  1437534_at 12.77 14.38 13.57 
Cxcl10  1418930_at 11.93 14.05 12.99 
Ccl5  1418126_at 18.09 7.72 12.90 
4930528F23Rik  1431648_at 11.42 13.89 12.65 
Tmem176a  1423909_at 12.19 12.23 12.21 
Tmem176b  1418004_a_at 6.94 17.37 12.15 
Tmem176a  1441811_x_at 9.88 14.23 12.06 
Zfp711  1432750_at 2.43 21.60 12.01 
Gfra2  1433716_x_at 10.93 11.62 11.27 
Gbp2  1418240_at 18.08 3.54 10.81 
Rbp2  1422846_at 10.15 11.18 10.66 
H2-K1  1427746_x_at 3.21 18.03 10.62 
Dclk1  1424270_at 17.32 2.78 10.05 
A730089K16Rik  1437263_at 9.50 10.33 9.92 
Stab1  1450199_a_at 12.79 5.73 9.26 
Fabp4  1417023_a_at 6.79 11.05 8.92 
Gpr176  1442116_at 13.98 2.37 8.17 
Vgf  1436094_at 6.44 7.79 7.11 
Tnfrsf9  1460469_at 9.76 4.08 6.92 
1700049E17Rik2  1430323_at 2.71 10.58 6.65 
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Table 3.1 (continued). 
    Experiment 1 Experiment 2   
Gene Symbol Probeset Fold Change Fold Change Average 
Rrad  1422562_at 10.91 2.04 6.48 
Nfkbie  1431843_a_at 7.86 5.00 6.43 
Ncf4  1418465_at 4.44 8.31 6.37 
Cd82  1416401_at 4.36 7.82 6.09 
Ubash3a  1431698_at 3.49 8.30 5.89 
Slc39a4  1451139_at 5.69 5.45 5.57 
Ccl2  1420380_at 5.33 5.50 5.42 
Ass1  1416239_at 5.90 4.86 5.38 
Dram1  1424524_at 2.79 7.96 5.37 
Ccdc34  1453758_at 7.29 2.88 5.08 
Tpbpa  1415809_at 5.67 4.44 5.05 
Slc26a3  1427547_a_at 2.79 6.90 4.85 
Ccl7  1421228_at 5.66 4.03 4.84 
Dclk1  1424271_at 6.79 2.83 4.81 
Ecscr  1437451_at 5.26 4.15 4.71 
Cxcl1  1457644_s_at 7.08 2.33 4.71 
Arhgef3  1424250_a_at 4.06 5.18 4.62 
Mmp13  1417256_at 5.05 4.07 4.56 
Fas  1460251_at 6.49 2.57 4.53 
Rnd1  1455197_at 6.00 2.49 4.25 
Cxcl1  1419209_at 4.87 3.58 4.22 
Ikbke  1417813_at 4.42 3.77 4.10 
Samsn1  1421457_a_at 5.05 3.06 4.06 
Relb  1417856_at 4.46 3.54 4.00 
Hcn1  1450193_at 3.86 3.70 3.78 
Nfkbia  1448306_at 4.77 2.77 3.77 
Vegfc  1419417_at 3.48 3.77 3.63 
LOC100044874  1424948_x_at 2.79 4.31 3.55 
Sdk1  1440566_at 2.57 4.47 3.52 
Trim66  1456967_at 3.35 3.34 3.35 
Gm9855  1454180_at 2.86 3.80 3.33 
Vegfc  1439766_x_at 3.42 3.14 3.28 
Col8a1  1418441_at 4.50 2.04 3.27 
Nfkbia  1449731_s_at 3.55 2.82 3.19 
Vegfc  1440739_at 3.62 2.73 3.18 
Pls1  1460406_at 4.26 2.01 3.13 
Dclk1  1451289_at 4.14 2.13 3.13 
Upp1  1448562_at 3.94 2.13 3.03 
Slc12a8  1420334_at 3.50 2.56 3.03 
Cxcl5  1419728_at 3.56 2.30 2.93 
 
  60
Table 3.1 (continued). 
    Experiment 1 Experiment 2   
Gene Symbol Probeset Fold Change Fold Change Average 
Col8a1  1418440_at 3.00 2.84 2.92 
Ptpn22  1417995_at 3.13 2.69 2.91 
Serpine2  1416666_at 2.35 3.24 2.80 
Gfra2  1459847_x_at 3.42 2.10 2.76 
Nlrp3  1425412_at 2.43 3.02 2.73 
Col8a1  1455627_at 2.55 2.83 2.69 
Cd34  1416072_at 2.65 2.73 2.69 
Gbp2  1435906_x_at 2.32 3.01 2.66 
Arhgdib  1426454_at 2.84 2.44 2.64 
Slc43a2  1434308_at 2.63 2.46 2.55 
Igfbp7  1423584_at 2.46 2.63 2.54 
Ubxn10  1426007_a_at 2.19 2.88 2.53 
Marcks  1415971_at 2.38 2.68 2.53 
Ttc39c  1426223_at 2.77 2.28 2.52 
Nfkbia  1438157_s_at 2.73 2.30 2.52 
Casp1  1449265_at 2.35 2.53 2.44 
Clec4e  1420330_at 2.56 2.26 2.41 
Scin  1450276_a_at 2.60 2.22 2.41 
Rims1  1438305_at 2.07 2.71 2.39 
Zfpm2  1444803_at 2.38 2.38 2.38 
C1s Gm5077  1424041_s_at 2.48 2.26 2.37 
Mmp3  1418945_at 2.55 2.18 2.37 
H2-K1  1425336_x_at 2.62 2.10 2.36 
Casp12  1449297_at 2.09 2.56 2.33 
Limd2  1447766_x_at 2.01 2.64 2.32 
Fjx1  1422733_at 2.57 2.06 2.32 
Cxcl1  1441855_x_at 2.11 2.52 2.32 
Nfasc  1459113_at 2.33 2.21 2.27 
Med8  1442417_at 2.06 2.40 2.23 
Nfkbia  1420088_at 2.19 2.09 2.14 
Pdgfra  1421917_at 2.19 2.07 2.13 
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cells compared to LLC-OVA-MiG cells. These included multiple chemokines 
involved in both T cell and neutrophil chemotaxis (Fig 3.6A, Table 3.2). Amongst 
T cell chemokines identified, CCL2, CCL5 and CXCL10 are known to mediate 
activated T cell chemotaxis (139). RT-PCR confirmed upregulation of CCL2, 
CCL5 (Fig 3.6B) and other chemokines (data not shown) in LLC-OVA-IKK. CCL2 
in particular exhibited high net expression in LLC-OVA-IKK (Fig 3.6A). Previous 
studies have indicated conflicting roles for CCL2 in anti-tumor T cell responses 
and an important role in breast cancer metastasis (140-142). Given these diverse 
functions, we determined whether CCL2 was specifically required for rejection of 
LLC-OVA-IKK by knockdown (KD) of CCL2 expression with shRNA-expressing 
lentiviruses. We identified an shRNA that led to greater than 80% reduction in 
CCL2 protein expression by ELISA (Fig 3.6C). CCL2 KD did not impact LLC 
growth in vitro (data not shown). LLC-OVA-IKK transduced with control or CCL2 
lentivirus resulted in similar expansion of OVA-specific T cells (Fig 3.6 D). 
However, while control LLC-OVA-IKK tumors were readily rejected, CCL2 KD 
resulted in robust tumor growth (Fig 3.6E). These results therefore identify CCL2 
as a crucial NF-κB target gene that is required for LLC rejection.  
 
3.5. Discussion 
 The tumor promoting functions of NF-κB have been extensively 
documented. We report here that in immunogenic tumors or following 
administration of anti-tumor vaccines, high NF-κB activity leads to tumor rejection 
and/or retardation of tumor growth.  
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A. 
B. 
Figure 3.6. Impact of T cell chemokines on tumor rejection. (A)Transcript signal 
(left) and fold increase (right) of chemokines induced by LLC-OVA-IKK at least 
two-fold over LLC-OVA-MiG determined by microarray. Genes reported as 
mean +/- SEM. (B) Tetramer analysis of peripheral blood on D14 from naïve 
mice or mice receiving LLC-OVA-IKK, LLC-OVA-IKK-Lenti control or LLC-OVA-
IKK-CCL2. Each point represents data from a single mouse. (C) RT-PCR 
showing CCL2 and CCL5 expression in LLC parental, LLC transduced with 
OVA and LLC transduced with OVA+MiG or OVA+IKK. Results normalized to β-
actin levels. Samples were run in triplicate and reported as average +/- SEM. 
(E) LLC-OVA-IKK-Lenti control and LLC-OVA-IKK-CCL2 cells were injected s.c. 
in C57Bl/6 mice and tumor growth was monitored. Each line represents growth 
in a single mouse.  All results are representative of at least two independent 
experiments.  
C. 
D. E. 
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Table 3.2. Positive impact of IKKβ on chemokines expressed in LLC-OVA tumor 
cells. Chemokines were identified as being increased over 2-fold in LLC-OVA-
IKK cells compared to LLC-OVA-MiG cells by mircroarray. Genes are listed in 
order of decreasing fold-induction. 
    Experiment 1 Experiment 2 Average 
Gene Symbol Probeset Fold Induction Fold Induction Fold Induction 
Cxcl10  1418930_at 11.93 14.05 12.99 
Ccl5  1418126_at 18.09 7.72 12.90 
Ccl2  1420380_at 5.33 5.50 5.42 
Ccl7  1421228_at 5.66 4.03 4.84 
Cxcl1  1457644_s_at 7.08 2.33 4.71 
Cxcl1  1419209_at 4.87 3.58 4.22 
Cxcl5  1419728_at 3.56 2.30 2.93 
Cxcl1  1441855_x_at 2.11 2.52 2.32 
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 Using tumors rendered immunogenic by antigen expression or following 
administration of anti-tumor vaccines, we found that high NF-κB activity leads to 
tumor rejection and/or growth suppression. Studies in RAG2-/- mice, which lack 
an adaptive immune system (143) and athymic nude mice that lack T cells (144) 
suggested regression was mediated in a T cell-dependent manner. Growth of 
LLC-OVA-MiG tumors was substantially reduced in athymic nude mice compared 
to RAG2-/- mice. This is most likely due to enhanced cytotoxic activity of natural 
killer (NK) cells present in the athymic nude mice (145).  
We determined that the immunogenic tumors expressing IKK were 
capable of increased recruitment of T cells through increased expression of T cell 
chemokines, such as CCL2 and CCL5. Whether the T cells present in the tumors 
are specific for the expressed antigen, Kb-OVA, remains to be determined; 
however, that is likely the case because IKK expression in non-immunogenic 
LLC tumors had no effect on growth. 
As mentioned above, T cell-mediated tumor regression was the result of 
increased chemokine expression in LLC-OVA-IKK cells. Microarray analysis of 
the tumor lines showed that the T cell chemokine CCL2 had the highest overall 
expression (although not the highest fold-induction). Knock-down of CCL2 in 
LLC-OVA-IKK abrogated tumor regression. Current research indicates conflicting 
roles for CCL2 in cancer (90, 140-142). The role of CCL2 may vary depending on 
its temporal and spatial expression pattern. Our model expressed CCL2 from the 
point of tumor ‘initiation’, and although tumors grew initially, early growth may 
have resulted from lower CCL2 levels. As the tumors got progressively larger, 
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more CCL2 was produced and the chemokine gradient increased allowing better 
recruitment of T cells.  
CCL2 was not the only T cell chemokine induced by IKK expression, nor 
did it have the highest fold-induction. Other chemokines identified by our 
microarray data may also be playing a role in T cell-mediated tumor regression. 
While our results indicate a crucial role for NF-κB regulated T cell chemokines in 
tumor rejection, multiple additional NF-κB controlled pathways (e.g. antigen 
processing and presentation, expression of T cell stimulatory cytokines) may also 
play an important role. 
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Chapter 4. Concluding remarks and implications of IKKβ-induced NF-κB 
activation 
 The transcription factor NF-κB is one of the main regulators of 
inflammation and the immune response. NF-κB is ubiquitously expressed and is 
capable of activating numerous varied genes, from those involved in inhibition of 
apoptosis to activation of the immune response. Underscoring its central role in 
immunity, it is also involved in numerous diseases, from infections to 
autoimmunity and cancer (31, 37, 48, 102). Activation of NF-κB through the 
classical pathway requires functional IKKβ (42). Using constitutively active IKKβ, 
the studies presented here highlight two host-beneficial roles of activation of the 
classical NF-κB pathway.  
 
4.1. IKKβ-induced inflammation impacts the kinetics but not the magnitude 
of the immune response to a viral vector 
 In the second chapter, we examined the role of IKKβ-induced NF-κB 
activation of an immune response to a viral vaccine vector. We found that IKKβ 
was capable of enhancing the kinetics of the immune response, but not the 
magnitude of the response. This impact is most likely through the induction of 
inflammatory cytokines, such as TNFα induced by IKKβ that are capable of 
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increasing lymphocyte trafficking to lymph nodes (120). Importantly, these results 
were only evident in cases of robust inflammation, as subcutaneous 
administration of AdIKK, which did not induce noticeable inflammation, was 
incapable of enhancing the kinetics of the immune response.   
Surprisingly, while AdIKK induced increased expression of inflammatory 
cytokines and maturation markers in BMDCs, these increases were unable to 
enhance activation of T cells by the BMDCs over AdGFP infected BMDCs. 
Infection of BMDCs with adenovirus alone makes them capable of inducing a T 
cell response both in vitro and in vivo in an NF-κB-dependent manner (72). 
Because adenovirus already activates T cells in an NF-κB dependent manner, 
any further activation of DC through NF-κB may have minimal effect on T cell 
activation.   
One additional caveat of our in vivo BMDC results is that the SIINFEKL 
OVA peptide is a very strong activator of T cells. Uninfected BMDC pulsed with 
SIINFEKL activated CD8 T cells to a similar level as our SIINFEKL-pulsed and 
AdIKK infected BMDC (Fig 2.3D). It would be interesting to examine the impact 
of AdIKK infection of BMDC in a less immunogenic setting, such as that of an 
anti-tumor immune response. Current dendritic cell based vaccines for tumor 
immunotherapy have fallen short of the goal of tumor eradication. This is due, at 
least in part, to the tolerogenic tumor microenvironment (66). In this setting, 
AdIKK infection of dendritic cells may be able to improve the anti-tumor immune 
response by overcoming tolerance. To examine this possibility, one could inject 
mice with tumor cells expressing known tumor associated antigens (TAA). These 
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mice could then be treated with DCs pulsed with the TAAs and infected with 
AdIKK.   
In a similar study, AdNIK was shown to strongly enhance the magnitude of 
an adaptive immune response in an adenovirus vaccine setting (119). Here, 
AdNIK enhanced the type I T helper response through increased IgG2a 
production, T cell proliferation, IFN-γ production and cytotoxic T cells. NIK is also 
capable of activate IKKα and subsequent IRF family members (121, 122). This 
cooperative activation of NF-κB and IRF may explain the positive findings of 
Andreakos, et al.  
In our hands, compared to AdIKK, AdNIK was unable to increase 
maturation markers in BMDCs, nor could it increase nuclear translocation of NF-
κB family members. We did not examine the differences between the two viruses 
further since our AdNIK showed no difference in our preliminary studies 
compared to the control virus. Importantly, AdNIK was capable of increasing the 
expression of NF-κB target genes (IL-6, IL-12p35, and IL-12p40) in DCs at least 
two-fold compared to control.  These results confirm that our AdNIK is functional, 
just not to the extent seen by Andreakos, et al. Interestingly, the predominant NF-
κB subunit found in nuclear extracts from murine DCs infected with AdNIK was 
RelB, with some increase in p50. RelA, cRel, and p52 levels were similar to 
levels from AdGFP infected DCs. Infection of human HEK-293T cells with AdNIK 
resulted in nuclear levels of RelA and cRel similar to AdIKK-induced levels. The 
reasons for the differences between the two studies remain unclear; however, 
the majority of their in vitro work was completed with human DC, whereas our 
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comparison studies were done with murine DCs. The results from our western 
blots suggest that AdNIK is a more potent activator of NF-κB in human cells (our 
construct as well as that of Andreakos, et al uses human NIK). An additional 
difference between the two studies is that we used 2.5x less adenovirus to infect 
murine DCs, thus, any activation they saw in murine DC may be due to the 
higher viral titer.  
Major efforts are underway to understand how successful vaccines work 
and to define novel adjuvants that can enhance protective adaptive immunity. 
While virtually all microbial adjuvants activate NF-κB and IRF pathways (4, 63), 
their specific functions in promoting adaptive immunity are not clear.  Our results 
indicate that inflammation induced by IKKβ activation of the canonical NF-κB 
pathway impacts the kinetics but not the magnitude of the immune response to 
an adenovirus-encoded antigen. These findings suggest that AdIKK may be 
useful as an adjuvant to induce a more rapid immune response in a pulmonary 
disease setting. Importantly, these results help define the individual role of a key 
pathway induced by vaccine adjuvants.  
The techniques developed in chapter 2 are now a powerful tool that can 
help us 1) identify the roles of other transcription factors (IKKα, NIK, IRF3) 
involved in the induction of adaptive immunity to adenovirus, either individually or 
combined, and 2) determine if activation of these pathways can act impact on our 
understanding of adenoviral immunity as well as the development of adenoviral 
vaccine vectors.    
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4.2. Crucial role of NF-κB in T cell mediated immune surveillance in murine 
lung cancer 
In chapter 3, we examined the role of IKKβ-induced NF-κB in T cell 
mediated tumor immune responses. The role of NF-κB in tumor promotion is well 
documented in numerous cancer types (78, 79, 83-87). Despite the 
overwhelming evidence that NF-κB activation promotes cancer, we show here 
that IKKβ-induced activation of NF-κB can promote immune surveillance in at 
least a subset of tumors. 
Using tumors rendered immunogenic by antigen expression or following 
administration of anti-tumor vaccines, we found that high NF-κB activity leads to 
tumor rejection and/or growth suppression. Studies in RAG2-/- mice, which lack 
an adaptive immune system (146) and athymic nude mice that lack T cells (144) 
suggested regression was mediated in a T cell-dependent manner. We 
determined that the immunogenic tumors expressing IKK were capable of 
increased recruitment of T cells through increased expression of T cell 
chemokines, such as CCL2 and CCL5. Whether the T cells present in the tumors 
are specific for the expressed antigen, Kb-OVA, remains to be determined; 
however, that is likely the case because IKK expression in non-immunogenic 
LLC tumors had no effect on growth. This question can easily be answered by 
using H2Kb-OVA tetramer to stain for T cells in tumors prior to regression. 
As mentioned above, T cell-mediated tumor regression was the result of 
increased chemokine expression in LLC-OVA-IKK cells. Microarray analysis of 
the tumor lines showed that the T cell chemokine CCL2 had the highest overall 
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expression (although not the highest fold-induction). Knock-down of CCL2 in 
LLC-OVA-IKK abrogated tumor regression. Current research indicates conflicting 
roles for CCL2 in cancer (90, 140-142). The role of CCL2 may vary depending on 
its temporal and spatial expression pattern. Our model expressed CCL2 from the 
point of tumor ‘initiation’, and although tumors grew initially, early growth may 
have resulted from lower CCL2 levels. As the tumors got progressively larger, 
more CCL2 was produced and the chemokine gradient increased allowing better 
recruitment of T cells.  
CCL2 was not the only T cell chemokine induced by IKK expression, nor 
did it have the highest fold-induction. The other chemokines identified by our 
microarray data may also be playing a role in T cell-mediated tumor regression. 
CCL2 may not be the only chemokine involved; however, loss of CCL2 is enough 
to abrogate tumor regression in mice. To determine if CCL2 is sufficient for tumor 
regression, CCL2 must be over-expressed in LLC-OVA cells. If tumors 
expressing CCL2 regress, it will demonstrate that CCL2 is sufficient for recruiting 
CD8 T cells and mediating tumor regression. If tumors do not regress, it will 
indicate that CCL2 induction by IKK is necessary but not sufficient for tumor 
regression.  
The mechanisms that determine whether NF-κB functions to promote 
tumorigenesis or to promote anti-tumor immune responses remain to be 
determined. The roles of individual members of the NF-κB family, as well as the 
two pathways of activation need to be examined more closely. Knock-down of 
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individual subunits may provide a clue as to what is driving these opposing 
functions of NF-κB.   
Clinically, NF-κB is thought of as something that should be inhibited in the 
treatment of cancers. Here, we have shown that activation of NF-κB can promote 
anti-tumor immune responses. Using constitutively active IKK is not a feasible 
option for the treatment of cancers due to its known role in mediating 
tumorigenesis and the substantial technical difficulties involved (147, 148). 
However, identifying tumors displaying elevated NF-κB immune surveillance 
functions may allow us to target them for immunotherapy. Based on our findings, 
we would expect greater response to immunotherapy in NF-κB high versus NF-
κB low tumors.  
Although NF-κB is typically associated with tumor promotion, we show 
here that expression of NF-κB in lung tumors can enhance the anti-tumor 
immune response. In mice, this surveillance is mediated by elevated chemokine 
expression resulting in increased T cell recruitment to the tumor.  
 
4.3. Concluding remarks 
 NF-κB is involved in the activation of many genes regulating the immune 
response. Focusing on activation of the classical pathway of NF-κB through 
IKKβ, we present two stories that highlight the ability of NF-κB to enhance the 
immune response. In chapter 2, we show that increased activation of NF-κB in 
an adenoviral vaccine setting can improve the kinetics of the immune response. 
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In the third chapter, we show evidence supporting NF-κB activation as a 
mediator of increased tumor immune surveillance. These two studies provide 
new insights into NF-κB activation of the immune response that can be 
harnessed for improved treatment of diseases, including cancer. 
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